Company Analysis Kaken Pharmaceutical Co., Ltd.
1. Summary
Advantages
- Dividends (5.72%) are higher than the sector average (2.61%).
- The stock's return over the last year (35.05%) is higher than the sector average (-0.6139%).
- Current debt level 2.24% is below 100% and has decreased over 5 years from 2.49%.
- The company's current efficiency (ROE=5.73%) is higher than the sector average (ROE=-9.32%)
Disadvantages
- Price (3548 Β₯) is higher than fair price (2073.93 Β₯)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Kaken Pharmaceutical Co., Ltd. | Healthcare | Index | |
|---|---|---|---|
| 7 days | 6.2% | -0% | -0.7% |
| 90 days | 16.9% | -0% | -0% |
| 1 year | 35.1% | -0.6% | 17.3% |
4521 vs Sector: Kaken Pharmaceutical Co., Ltd. has outperformed the "Healthcare" sector by 35.67% over the past year.
4521 vs Market: Kaken Pharmaceutical Co., Ltd. has outperformed the market by 17.75% over the past year.
Stable price: 4521 is not significantly more volatile than the rest of the market on "Tokyo Stock Exchange" over the last 3 months, with typical variations of +/- 5% per week.
Long period: 4521 with weekly volatility of 0.6741% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (3548 Β₯) is higher than the fair price (2073.93 Β₯).
Price is higher than fair: The current price (3548 Β₯) is 41.5% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (16.89) is lower than that of the sector as a whole (110.91).
P/E vs Market: The company's P/E (16.89) is lower than that of the market as a whole (117.01).
4.2.1 P/E Similar companies
4.3. P/BV
P/BV vs Sector: The company's P/BV (0.9427) is lower than that of the sector as a whole (70.32).
P/BV vs Market: The company's P/BV (0.9427) is lower than that of the market as a whole (84.1).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (1.88) is lower than that of the sector as a whole (75.03).
P/S vs Market: The company's P/S indicator (1.88) is lower than that of the market as a whole (84.05).
4.4.1 P/S Similar companies
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (7.06) is lower than that of the sector as a whole (18.74).
EV/Ebitda vs Market: The company's EV/Ebitda (7.06) is lower than that of the market as a whole (90.65).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Negative and has fallen by -11.71% over the last 5 years.
Accelerating profitability: The return for the last year (0%) exceeds the average return for 5 years (-11.71%).
Profitability vs Sector: The return for the last year (0%) is lower than the return for the sector (0.4856%).
5.4. ROE
ROE vs Sector: The company's ROE (5.73%) is higher than that of the sector as a whole (-9.32%).
ROE vs Market: The company's ROE (5.73%) is lower than that of the market as a whole (7.7%).
5.5. ROA
ROA vs Sector: The company's ROA (4.75%) is higher than that of the sector as a whole (-9.68%).
ROA vs Market: The company's ROA (4.75%) is higher than that of the market as a whole (3.9%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (7.92%) is lower than that of the sector as a whole (9.09%).
ROIC vs Market: The company's ROIC (7.92%) is lower than that of the market as a whole (8.77%).
7. Dividends
7.1. Dividend yield vs Market
High yield: The dividend yield of the company 5.72% is higher than the average for the sector '2.61%.
7.2. Stability and increase in payments
Dividend stability: The company's dividend yield 5.72% has been steadily paid over the past 7 years, DSI=0.86.
Weak dividend growth: The company's dividend yield 5.72% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (70.49%) are at a comfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
